Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
For instance, a number of ongoing or completed trials are evaluating inhibitors of the PI3K-AKT-mTOR cascade, such as gedatolisib (NCT03065062) in advanced solid tumors, capivasertib (NCT04305496) in hormone receptor-positive breast cancer, and alpelisib (NCT02437318), which has shown efficacy in advanced breast cancer and is already approved for PIK3CA-mutated cases
Important Takeaway: Think of these supplements as proactive support, not a reactive fix
The listing of any company or its logos is not intended to imply any endorsement or direct affiliation with said company
Aspects of Med
US$ 22.92
US$ 29.86
US$ 26.48
US$ 24.93
